173 related articles for article (PubMed ID: 2884031)
1. Characterization in vitro and in vivo of progressively adriamycin-resistant B16-BL6 mouse melanoma cells.
Ganapathi R; Grabowski D; Schmidt H; Bell D; Melia M
Cancer Res; 1987 Jul; 47(13):3464-8. PubMed ID: 2884031
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
Gautam SC; Chikkala NF; Lewis I; Grabowski DR; Finke JH; Ganapathi R
Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150
[TBL] [Abstract][Full Text] [Related]
3. Abnormally banded chromosomal regions in doxorubicin-resistant B16-BL6 murine melanoma cells.
Slovak ML; Hoeltge GA; Ganapathi R
Cancer Res; 1986 Aug; 46(8):4171-7. PubMed ID: 3731084
[TBL] [Abstract][Full Text] [Related]
4. Carbohydrate chain analysis by lectin binding to electrophoretically separated glycoproteins from murine B16 melanoma sublines of various metastatic properties.
Irimura T; Nicolson GL
Cancer Res; 1984 Feb; 44(2):791-8. PubMed ID: 6692378
[TBL] [Abstract][Full Text] [Related]
5. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
Ganapathi R; Grabowski D; Sweatman TW; Seshadri R; Israel M
Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093
[TBL] [Abstract][Full Text] [Related]
6. In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone.
Gutierrez PL; Wilder PJ; Biswal N
Cancer Commun; 1989; 1(3):181-90. PubMed ID: 2576972
[TBL] [Abstract][Full Text] [Related]
7. Characterization of B16 melanoma cells resistant to the CC-1065 analogue U-71,184.
Moy BC; Petzold GL; Badiner GJ; Kelly RC; Aristoff PA; Adams EG; Li LH; Bhuyan BK
Cancer Res; 1990 Apr; 50(8):2485-92. PubMed ID: 2317831
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of a Mr approximately 90,000 cell surface transferrin receptor-related glycoprotein on murine B16 metastatic melanoma sublines selected for enhanced brain or ovary colonization.
Nicolson GL; Inoue T; Van Pelt CS; Cavanaugh PG
Cancer Res; 1990 Feb; 50(3):515-20. PubMed ID: 2297694
[TBL] [Abstract][Full Text] [Related]
9. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
[TBL] [Abstract][Full Text] [Related]
10. Biological characterization of multidrug-resistant human colon carcinoma sublines induced/selected by two methods.
Yang LY; Trujillo JM
Cancer Res; 1990 Jun; 50(11):3218-25. PubMed ID: 2334917
[TBL] [Abstract][Full Text] [Related]
11. Effects of tunicamycin on B16 metastatic melanoma cell surface glycoproteins and blood-borne arrest and survival properties.
Irimura T; Gonzalez R; Nicolson GL
Cancer Res; 1981 Sep; 41(9 Pt 1):3411-8. PubMed ID: 7260906
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine and phenylalanine restriction sensitizes adriamycin-resistant P388 leukemia cells to adriamycin.
Elstad CA; Thrall BD; Raha G; Meadows GG
Nutr Cancer; 1996; 25(1):47-60. PubMed ID: 8837861
[TBL] [Abstract][Full Text] [Related]
13. Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance.
Ganapathi R; Schmidt H; Grabowski D; Melia M; Ratliff N
Br J Cancer; 1988 Sep; 58(3):335-40. PubMed ID: 3179186
[TBL] [Abstract][Full Text] [Related]
14. Growth characteristics of clonal cell populations constituting a B16 melanoma metastasis model system.
Stackpole CW; Alterman AL; Fornabaio DM
Invasion Metastasis; 1985; 5(3):125-43. PubMed ID: 3888909
[TBL] [Abstract][Full Text] [Related]
15. Identification of genes differentially expressed in B16 murine melanoma sublines with different metastatic potentials.
Ishiguro T; Nakajima M; Naito M; Muto T; Tsuruo T
Cancer Res; 1996 Feb; 56(4):875-9. PubMed ID: 8631027
[TBL] [Abstract][Full Text] [Related]
16. Anti-cell death activity promotes pulmonary metastasis of melanoma cells.
Takaoka A; Adachi M; Okuda H; Sato S; Yawata A; Hinoda Y; Takayama S; Reed JC; Imai K
Oncogene; 1997 Jun; 14(24):2971-7. PubMed ID: 9205104
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
Slovak ML; Hoeltge GA; Dalton WS; Trent JM
Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069
[TBL] [Abstract][Full Text] [Related]
18. In vitro selection and characterization of a bleomycin-resistant subline of B16 melanoma.
Zuckerman JE; Raffin TA; Brown JM; Newman RA; Etiz BB; Sikic BI
Cancer Res; 1986 Apr; 46(4 Pt 1):1748-53. PubMed ID: 2418953
[TBL] [Abstract][Full Text] [Related]
19. Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth.
Gil-Ad I; Shtaif B; Levkovitz Y; Nordenberg J; Taler M; Korov I; Weizman A
Oncol Rep; 2006 Jan; 15(1):107-12. PubMed ID: 16328041
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D
Cancer Res; 1983 Aug; 43(8):3696-9. PubMed ID: 6861140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
